Response Pharmaceuticals

Response Pharmaceuticals is a clinical-stage pharmaceutical company developing targeted therapies for weight management and metabolic health. Its lead candidate, RDX-002, is a novel small-molecule intestinal microsomal triglyceride transfer protein (iMTP) inhibitor.

The candidate is being developed for two disclosed indications: weight management in patients discontinuing GLP-1 receptor agonists (post-GLP-1 receptor agonist weight management) and antipsychotic-induced weight gain (AIWG). RDX-002 has progressed from Phase 1b into Phase 2 clinical testing, with top-line and 36-week Phase 2 results reported for the post-GLP-1 setting and Phase 1b primary endpoint achievement reported in AIWG.

Traction

Clinical milestones reported on the company's site include successful completion of a Phase 1b trial of RDX-002 (August 2023), achievement of the primary endpoint in a Phase 1b trial in antipsychotic-induced weight gain (April 2024), enrollment of first patients in a Phase 2 study in patients discontinuing GLP-1 agonists together with a clinical presentation at Obesity Week (October 2024), early completion of enrollment in that Phase 2 study (February 2025), positive top-line Phase 2 results in post-GLP-1 management (August 2025), and positive 36-week Phase 2 data (March 2026).

Latest developments

In March 2026 the company reported positive 36-week Phase 2 data supporting RDX-002 as a long-term option in post-GLP-1 receptor agonist weight management, and it announced plans to present RDX-002 data in antipsychotic-induced weight gain at the 2026 American Psychiatric Association Annual Meeting in May 2026.